NCT06071156View on ClinicalTrials.gov

Therapy Management in Patients Treated With Anakinra Due to Recurrent Pericarditis

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

May 5, 2022

Study Completion Date

January 31, 2025

Conditions
Recurrent Pericarditis
Interventions
DRUG

Anakinra

Anakinra, an IL-1 antagonist, is particularly interesting because it limits the self-sustained pathway of recurrent pericarditis and may reduce the recurrences

Trial Locations (1)

60123

RECRUITING

CCPC, Ancona

All Listed Sponsors
lead

Azienda Ospedaliero, Universitaria Ospedali Riuniti

OTHER